Kimball Electronics Inc (KE) Q3 2026 Earnings Call Transcript

Why It Matters

The shift toward higher‑margin medical contract manufacturing aims to offset automotive weakness and drive sustainable earnings growth. Investors should watch the new CMO capacity and working‑capital initiatives as key levers for future profitability.

Key Takeaways

• Medical revenue up 5% YoY, now 28% of sales
• Automotive sales down 13% after braking program loss
• Gross margin fell to 8% but shows sequential improvement
• Debt reduced 50%; liquidity stands at $380.5M
• FY2026 sales guidance down 2‑9% with 4‑4.25% margin

Pulse Analysis

Kimball Electronics’ fourth‑quarter results underscore a pivotal transition from traditional automotive electronics toward a medical‑focused contract manufacturing model. While total revenue slipped to $381 million, the company’s medical segment delivered a 5% year‑over‑year increase, now accounting for over a quarter of sales. This growth is anchored by a sole‑source agreement for respiratory‑care assemblies and a broader push into cardiology, orthopedics, and drug‑delivery devices. The loss of the Reynosa electronic braking program removed roughly $60 million from the top line, highlighting the volatility of the automotive segment and prompting a strategic realignment.

The centerpiece of Kimball’s new direction is the 300,000‑square‑foot Indianapolis facility, slated to open in November. Designed for high‑value, high‑complexity medical assemblies, the plant promises “well in excess of half a billion” dollars of revenue potential and significant automation to lift gross margins. Management projects adjusted SG&A expenses to fall to about 3.5% of revenue, while the effective tax rate is expected to settle in the low‑30% range, further enhancing net profitability. These operational upgrades are complemented by a disciplined balance‑sheet approach that cut borrowings by 50% and improved cash conversion days to 85, positioning the company for agile capital deployment.

Looking ahead, Kimball forecasts FY2026 net sales between $1.35 billion and $1.45 billion, reflecting a 2%‑9% decline primarily due to the automotive downturn and the absence of a large consigned inventory sale. However, the guidance assumes a flat‑to‑modest rise in medical and industrial revenues, offset by continued automotive weakness. Investors should monitor the ramp‑up of the Indianapolis CMO capacity, the effectiveness of working‑capital initiatives, and the company’s ability to sustain margin expansion amid a shifting product mix. The firm’s strategic pivot, combined with a stronger liquidity position, could re‑anchor growth trajectories and deliver more resilient earnings in a post‑automotive‑recession landscape.